A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Stephen Director, Clinical Operations
- Phone Number: 551-265-2151
- Email: sgust@viridiantherapeutic.com
Study Locations
-
-
-
Angers, France
- Servicde d'Endocrinologie, Diabetologieet Nutrition Centre Hospitalier Universitaire d'Angers
-
Bron, France, 69500
- Abeillon du Payrat
-
Paris, France
- Hôpital La Pitiélsalpêtrière
-
-
-
-
-
Berlin, Germany
- Charite Universitatsmeizin Berlin KoR Campus Virchow Klinikum
-
Essen, Germany
- Universitätsklinikum Essen
-
Göttingen, Germany, 37075
- Universitaetsmedizin Goettingen
-
Mainz, Germany
- Johannes Gutenberg University Medical Center Department of Medicine 1
-
-
-
-
-
Bialystok, Poland, 15-276
- Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Okulistyki, Centrum Badań Klinicznych
-
Gdansk, Poland, 80-180
- Optimum Profesorskie Centrum Okulistyki Sp. z o. o.
-
Gdynia, Poland, 81-338
- Centrum Medyczne Pratia Gdynia
-
Lodz, Poland, 90-302
- Santa Familia PTG Lodz
-
Lublin, Poland, 20-412
- ETG Lublin
-
Piaseczno, Poland, 05-500
- Centrum Medyczne Pulawska Sp. z o.o.
-
Warsaw, Poland, 01-258
- Warszawski Szpital Okulistyczny
-
Warsaw, Poland, 02-777
- Polimedica PTG
-
-
-
-
-
A Coruña, Spain, 15706
- Hospital Provincial de Conxo
-
Barcelona, Spain, 08017
- Institut Catalâ de Retina
-
Córdoba, Spain, 14012
- Hospital La Arruzafa
-
Madrid, Spain, 28034
- Hospital Universitario Ramon y Cajal
-
Navarrés, Spain
- Clinica Universidad de Navarre
-
Seville, Spain, 41009
- Hospital Universitario Virgen Macarena
-
Zaragoza, Spain
- Hospital Universitario Miguel Servet Consultas de Oftalmologia
-
-
-
-
-
Ankara, Turkey (Türkiye)
- Gazi University Medical Faculty Hospital
-
Ankara, Turkey (Türkiye)
- Hacettepe Univeristy Medical Fculty Hospital
-
Antalya, Turkey (Türkiye), 07059
- Akdeniz Üniversitesi Tıp Fakültesi Göz Hastalıkları Anabilim Dalı
-
Istanbul, Turkey (Türkiye)
- Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi Göz Hastalıkları Kliniği
-
-
-
-
-
Bristol, United Kingdom
- University Hospitals Bristol and Weston NHS Foundation Trust Clinical Research Unit
-
Cambridge, United Kingdom
- Addenbrookes Hospital
-
London, United Kingdom, SE1 7EH
- Guy's and St Thomas' NHS Foundation Trust
-
London, United Kingdom, NW1 5QH
- Imperial College Healthcare NHS Trust
-
London, United Kingdom
- Moorefields Eye Hospital NHS Foundation Trust
-
Newcastle, United Kingdom
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust
-
-
-
-
Arizona
-
Tuscon, Arizona, United States, 85712
- Catalina Eye Care
-
-
California
-
Inglewood, California, United States, 90301
- United Medical Research Institute
-
Newport Beach, California, United States, 92660
- Orbital Plastics
-
Pasadena, California, United States, 91107
- California Eye Specialists Medical Group Inc
-
Pismo Beach, California, United States, 93030
- Fomat Medical Research
-
Santa Monica, California, United States, 90404
- Pacific Neuroscience Institute
-
Torrance, California, United States, 90503
- Pacific Neuroscience Institute at Saint John's Physician Partners
-
-
Florida
-
Cape Coral, Florida, United States, 33990
- C A Clinical Trial Corp.
-
Coral Gables, Florida, United States, 33134
- Herco Medical and Research Center
-
Davie, Florida, United States, 33024
- Alfa Medical Research
-
Doral, Florida, United States, 33132
- D H Doral Research Center
-
Fort Myers, Florida, United States, 33901
- Eye Centers of Florida
-
Homestead, Florida, United States, 33034
- Sina Medical Center
-
Jacksonville, Florida, United States, 32216
- East Coast Institute for Research, LLC
-
Miami, Florida, United States, 33144
- Continental Clinical Research
-
Miami, Florida, United States, 33125
- Southern Clinical Research LLc
-
Miami, Florida, United States, 33135
- Retreat Medical Research
-
Plantation, Florida, United States, 33317
- Edward Jenner Research Group LLC
-
Sarasota, Florida, United States, 34239
- Sarasota Retina Institute
-
-
Illinois
-
Orland Park, Illinois, United States, 60462
- Advanced Quality Medical Research
-
-
Massachusetts
-
East Weymouth, Massachusetts, United States, 02189
- Ophthalmic Consultants of Boston
-
-
Michigan
-
Fraser, Michigan, United States, 48026
- Fraser Eye Care Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Rochester
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- University of Missouri Kansas City
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- Rutgers New Jersey Medical School
-
-
Tennessee
-
Jackson, Tennessee, United States, 38305
- Jackson Clinic
-
-
Texas
-
Carrollton, Texas, United States, 75010
- DFW Clinical Trials
-
Houston, Texas, United States, 77099
- Pioneer Research Solutions Inc.
-
Houston, Texas, United States, 77074
- Neuro Eye Clinical Trials
-
San Antonio, Texas, United States, 78240
- San Antonio Clinical Trials
-
San Antonio, Texas, United States, 78258
- Eyeplastx
-
Seabrook, Texas, United States, 77586
- Elevate Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Have a clinical diagnosis of TED with or without proptosis and with any CAS (0-7) and in the opinion of the Investigator may benefit from VRDN-003
- Not require immediate ophthalmological or orbital surgery in the study eye for any reason.
- Must agree to use highly effective contraception as specified in the protocol
- Female TED participants must have a negative serum pregnancy test at screening
Key Exclusion Criteria:
- Must not have received prior treatment with another anti-IGF-1R therapy
- Must not have received systemic corticosteroids or steroid eye drops for any condition, including TED, or selenium within 2 weeks prior to first dose.
- Must not have received other immunosuppressive drugs for any condition, including TED, or any other therapy for TED within 12 weeks prior to first dose
- Must not have received an investigational agent for any condition, including TED, within 8 weeks or longer duration (depending on the type of investigational agent) prior to first dose
- Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose
- Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit
- Must not have a pre-existing ophthalmic condition in the study eye which in the study doctor's opinion, would interfere with interpretation of study results
- Must not have abnormal hearing test before first dose. Must also not have a history of ear conditions considered significant by study doctor
- Must not have a history of inflammatory bowel disease
- Female TED participants must not be pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: VRDN-003 every 4 weeks
6 subcutaneous administrations of VRDN-003
|
VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
|
|
Experimental: VRDN-003 every 8 weeks
3 subcutaneous administrations of VRDN-003 and 3 subcutaneous administrations of placebo
|
VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
Placebo injections that appear identical to VRDN-003 injections but have no active drug.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment Emergent Adverse Event (TEAE) incidence rate through Week 24
Time Frame: Week 24
|
Treatment Emergent Adverse Event (TEAE) incidence rate through Week 24
|
Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in proptosis in the study eye at Week 24 as measured by exophthalmometer
Time Frame: Week 24
|
Change from baseline in proptosis in the study eye
|
Week 24
|
|
TEAE incident rate through study completion
Time Frame: Week 52
|
Treatment Emergent Adverse Event (TEAE) incidence rate measurement through study completion
|
Week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Genetic Diseases, Inborn
- Autoimmune Diseases
- Immune System Diseases
- Eye Diseases
- Eye Diseases, Hereditary
- Graves Disease
- Exophthalmos
- Orbital Diseases
- Goiter
- Hyperthyroidism
- Thyroid Diseases
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Graves Ophthalmopathy
Other Study ID Numbers
Other Study ID Numbers
- VRDN-003-303
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.